Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.

Leukemia - 1 Jan 2006

Tchirkov A, Couderc J-L, Périssel B, Goumy C, Regnier A, Uhrhammer N, Verrelle P, Berger M

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Fusion Proteins, bcr-abl
Share to Gene Expression Regulation, Leukemic
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Pyrimidines

Share to Remission Induction

Source

Open in PubMed Open full text

Identifiers

PMID: 16270035
DOI: 10.1038/sj.leu.2404012
PMCID: PMC1931492

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.PMID 16270035Read ↗

Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes.Semantic proximity Read ↗

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.Semantic proximity Read ↗

A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD)Semantic proximity Read ↗

A Rare e14a3 (b3a3) BCR-ABL Fusion Transcript in Chronic Myeloid LeukemiaSemantic proximity Read ↗

CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.Semantic proximity Read ↗

E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib.Semantic proximity Read ↗

Imatinib resistance in chronic myeloid leukemia due to a rare mutation.Semantic proximity Read ↗

BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisisSemantic proximity Read ↗

Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of KashmirSemantic proximity Read ↗

[Chronic myeloid leukemia with variant e19a2 BCR-ABL1 fusion transcript: interest of the molecular identification at diagnosis for minimal residual disease follow-up].Semantic proximity Read ↗

A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative diseaseSemantic proximity Read ↗

Two cases of acute lymphoblastic leukemia with an e1a3 BCR-ABL1 fusion transcript.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.